Recent Phase 3 clinical trials have yielded three critical findings that reshape treatment paradigms for non-diabetic chronic kidney disease. First, finerenone demonstrates a robust 23% reduction in kidney disease progression in this historically under-served population. Second, the drug delivers consistent cardiovascular protection, reducing cardiovascular death risk by 14% regardless of diabetic status—a crucial consideration given the high cardiovascular mortality burden in CKD cohorts.
Third, finerenone maintains a manageable safety profile, broadening its potential application to millions of patients who previously exhausted conventional therapeutic options. These findings collectively suggest that mineralocorticoid receptor antagonism addresses disease mechanisms fundamental to CKD progression independent of glycemic status. For clinicians managing non-diabetic CKD patients, these results provide evidence-based rationale for considering finerenone as an additional protective strategy alongside established renin-angiotensin system inhibitors, offering meaningful benefit for a population with previously limited options.
Read the full article on GMJ Newsroom.
Was this article helpful?
